Lyell Immunopharma
LYEL · NASDAQ
$9.70+$0.90 (+10.23%)TodayMarket closed ·
Prev close $8.80
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 20.5% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$2.06 | -$1.92 | +6.7% |
| Q1 FY26 | -$2.41 | -$1.10 | +54.4% |
| Q4 FY25 | -$2.28 | -$7.50 | −229.5% |
| Q3 FY25 | -$2.70 | -$2.13 | +21.0% |
| Q2 FY25 | -$3.65 | -$2.89 | +20.9% |
| Q1 FY25 | -$3.67 | -$3.54 | +3.6% |
| Q4 FY24 | -$3.47 | -$4.00 | −15.3% |
| Q3 FY24 | -$4.08 | -$3.40 | +16.7% |
Earnings calls
- 2026 Global Healthcare Conference
- H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Stifel 2026 Targeted Oncology Virtual Forum
- H.C. Wainwright 4th Annual BioConnect Investor Conference
- 25th Annual Needham Virtual Healthcare Conference
- The Citizens Life Sciences Conference 2026
- Leerink Global Healthcare Conference 2026
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.